Canada markets closed

Syros Pharmaceuticals, Inc. (0S9.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.9068+0.0012 (+0.13%)
As of 08:20AM CEST. Market open.
Full screen
Previous Close0.9056
Open0.9068
Bid0.9112 x 0
Ask0.9292 x 0
Day's Range0.9068 - 0.9068
52 Week Range0.6436 - 4.7400
Volume250
Avg. Volume83
Market Cap60.407M
Beta (5Y Monthly)2.12
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Business Wire

    Syros to Present at JMP Securities Life Sciences Conference

    CAMBRIDGE, Mass., June 08, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate in a fireside chat at the JMP Securities Life Sciences Conference. Management will also be available for one-on-one meetings. Details are as follows:

  • Business Wire

    Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    CAMBRIDGE, Mass., June 03, 2022--Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an aggregate of 77,850 shares of Syros common stock to four newly hired employees in connection with their commencement of employment with Syros. These RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

  • Business Wire

    Syros Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides a Corporate Update

    CAMBRIDGE, Mass., May 16, 2022--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today reported financial results for the quarter ended March 31, 2022 and provided a corporate update.